Nabil Saba

Dr. Nabil Saba

Emory university school of medicine
+1
orcid
Professor and Vice Chair, Hematology and Medical Oncology, L...

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in The Lancet
Verified
Journal Article
Closed access
MMMayur D Mody
Mayur D Mody
JRJames W Rocco
James W Rocco
SYSue S Yom
Sue S Yom
RHRobert I Haddad
Robert I Haddad
Nabil SabaNabil Saba
Nabil Saba

29 November 2016 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
PDF file
CSConor E. Steuer
Conor E. Steuer
MEMark El‐Deiry
Mark El‐Deiry
JPJason R. Parks
Jason R. Parks
KHKristin A. Higgins
Kristin A. Higgins
Nabil SabaNabil Saba
Nabil Saba

10 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RFRobert L. Ferris
Robert L. Ferris
YFYael Flamand
Yael Flamand
GWGregory S. Weinstein
Gregory S. Weinstein
SLShuli Li
Shuli Li
HQHarry Quon
Harry Quon
BBBarbara Ann Burtness
Barbara Ann Burtness
PURPOSE: Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus–associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC. METHODS: E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS: Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented. CONCLUSION: Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.

31 January 2012 in Cancer
Verified
Journal Article
Open access
PDF file
CEChristopher L. Ellington
Christopher L. Ellington
MGMichael Goodman
Michael Goodman
SKScott A. Kono
Scott A. Kono
WGWilliam Grist
William Grist
TWTrad Wadsworth
Trad Wadsworth
Nabil SabaNabil Saba
Nabil Saba
BACKGROUND: Adenoid cystic carcinoma (ACC) of the head and neck (ACCHN) is a rare tumor of minor salivary, parotid, and submandibular glands. The biologic behavior of the disease is poorly understood, and nonsurgical treatment strategies have yet to be standardized. The long‐term prognosis continues to be guarded, with an estimated 10‐year survival of <60%. Population‐based studies examining ACC are scarce. The authors aimed to analyze incidence rates and survival outcomes for patients diagnosed with ACCHN using national population‐based data.METHODS: Data were obtained from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Newly diagnosed ACCHN cases reported to SEER from 1973 through 2007 were categorized according to their sex, race, age, year of diagnosis, marital status, treatment interventions, primary tumor site, and disease stage. Incidence of ACCHN and postdiagnosis survival were examined over time and compared across different demographic and disease‐related categories.RESULTS: The authors identified 3026 patients with ACCHN. The mean age at diagnosis among those cases was 57.4 years (range, 11‐99 years). Analyses of incidence data demonstrated a decline in ACCHN rates between 1973 and 2007, noted across all sexes and races with no detectable inflexion points. The overall 5‐year, 10‐year, and 15‐year survival outcomes for ACCHN patients were 90.3%, 79.9%, and 69.2%, respectively. Females, patients with localized disease, and younger patients were found to have significantly better survival across all time periods (all comparison‐specific log‐rank P values <0.001). Multivariate analyses revealed better prognosis among women compared with men (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.65‐0.82), among married compared with unmarried individuals (HR, 0.81; 95% CI, 0.71‐0.91), with certain sites of origin and stage of disease (HR, 2.788; 95% CI, 2.36‐3.29), and in those who had surgery of the primary tumor site (HR, 0.45; 95% CI, 0.37‐0.54).CONCLUSIONS: The overall incidence of ACC is declining. The noted differences in survival based on sex, marital status, site of origin, and treatment intervention require further investigation. Cancer 2012. © 2012 American Cancer Society

10 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
AHAlan L. Ho
Alan L. Ho
IBIrene Brana
Irene Brana
RHRobert Haddad
Robert Haddad
JBJessica Bauman
Jessica Bauman
KBKeith C. Bible
Keith C. Bible
AGAntonio Gualberto
Antonio Gualberto
PURPOSE: Mutations in the HRAS (m HRAS) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase inhibitor that disrupts HRAS function. We evaluated the efficacy of tipifarnib in patients with R/M m HRAS HNSCC.METHODS: We enrolled 30 patients with R/M HNSCC in a single-arm, open-label phase II trial of tipifarnib for m HRAS malignancies; one additional patient was treated on an expanded access program. After an ad hoc analysis of the first 16 patients with HNSCC with m HRAS variant allele frequency (VAF) data, enrollment was limited to those with a m HRAS VAF of ≥ 20% (high VAF). The primary end point was objective response rate. Secondary end points included assessing safety and tolerability. Patients received tipifarnib 600 or 900 mg orally twice daily on days 1-7 and 15-21 of 28-day cycles.RESULTS: Of the 22 patients with HNSCC with high VAF, 20 were evaluable for response at the time of data cutoff. Objective response rate for evaluable patients with high-VAF HNSCC was 55% (95% CI, 31.5 to 76.9). Median progression-free survival on tipifarnib was 5.6 months (95% CI, 3.6 to 16.4) versus 3.6 months (95% CI, 1.3 to 5.2) on last prior therapy. Median overall survival was 15.4 months (95% CI, 7.0 to 29.7). The most frequent treatment-emergent adverse events among the 30 patients with HNSCC were anemia (37%) and lymphopenia (13%).CONCLUSION: Tipifarnib demonstrated encouraging efficacy in patients with R/M HNSCC with HRAS mutations for whom limited therapeutic options exist ( NCT02383927 ).

14 May 2013 in Cancer
Verified
Journal Article
Open access
PDF file
BABenjamin E Ansa
Benjamin E Ansa
MGMichael Goodman
Michael Goodman
KWKevin Ward
Kevin Ward
SKScott A. Kono
Scott A. Kono
TOTaofeek K. Owonikoko
Taofeek K. Owonikoko
Nabil SabaNabil Saba
Nabil Saba
BACKGROUND: Paranasal sinus squamous cell carcinomas (PNSSCC) account for 3% of all head and neck malignancies. There has been little information on the trends in incidence and survival, and no randomized trials have been conducted to guide therapy.METHODS: Patients with PNSSCC reported to the Surveillance, Epidemiology, and End Results (SEER) Program from 1973 through 2009 were categorized by sex, age, year of diagnosis, primary site, stage, and treatment. The incidence and survival were then compared across different demographic and disease‐related categories by calculating rate ratios (RRs) and mortality hazard ratios along with the corresponding 95% confidence intervals (CIs).RESULTS: In total, 2553 patients with PNSSCC were identified. While incidence of PNSSCC showed a gradual decline, survival remained largely unchanged. The proportion of patients with advanced disease decreased from 14.7% during the period from 1983 to 1992 to 12.4% during 1993‐2002 and to 9.5% during 2003‐2009. Compared with whites, incidence was higher among African Americans (RR 1.63; 95% CI, 1.39, 1.90) and among all other racial groups (RR, 1.78; 95% CI: 1.53‐2.07). After adjusting for age, sex, disease stage, tumor site, and treatment, mortality among African American patients also was increased (hazard ratio, 1.22; 95% CI, 1.04‐1.43). Among patients with localized disease, the relation between race and mortality was no longer evident once the results were controlled for tumor classification.CONCLUSIONS: The current findings point to racial disparities in the incidence of PNSSCC and, to a lesser extent, in the outcome of patients with PNSSCC. Although there has been a decline in the proportion of patients presenting with advanced PNSSCC, the overall survival remained stable over time. Cancer 2013;119:2602–2610. © 2013 American Cancer Society.